Support for use of MDMA in medical trials and treatment U.S. 2017

Percentage of U.S. adults who supported allowing researchers to conduct medical trials with MDMA as of 2017

Loading statistic...
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

2017

Region

North America, United States

Survey time period

June 2 to 5, 2017

Number of respondents

1,125 respondents

Age group

18 years and older

Special properties

U.S. adults

Supplementary notes

Original question: In 2016, The FDA approved MDMA (also known as ecstasy) for Phase 3 clinical trials as a treatment for post-traumatic stress disorder (PTSD) — a final step before possible approval as a prescription drug. One study showed that with 3 doses of MDMA administered under a psychiatrist's guidance, the patients reported a 56% decrease of severity of symptoms on average. At the end of the study, 66% no longer met the criteria for having PTSD — improvements lasted more than a year after therapy. Do you support or oppose similar medical trials with MDMA being conducted in the future?

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Other regions

10

Related statistics

10

Further related statistics

8
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.